MedTrace Logo

The SIBERIA Trial (Acculink™ Versus CGuard™)

NCT03488199 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-10-08

No results posted yet for this study

Summary

That the study will be carried out as it has the protocol instructions, respecting the applicable regulations for clinical investigations with medical devices and following the internationally accepted ethical standards

Conditions

  • Patients With Aterosclerotic Carotid Stenosis
  • Symptomatic Patients (Stenosis > 50%)
  • Asymptomatic Patients (Stenosis ≥80%)

Interventions

DEVICE

Stent Acculink ™

Carotid Artery Revascularization using Stents

DEVICE

CGuardTM™

Carotid Artery Revascularization using Stents

Sponsors & Collaborators

  • Meshalkin Research Institute of Pathology of Circulation

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-11
Primary Completion
2021-02-11
Completion
2021-03-09

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03488199 on ClinicalTrials.gov